• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

DarioHealth touts data for diabetes management platform

July 1, 2021 By Sean Whooley

DarioHealthDarioHealth (NSDQ:DRIO) recently presented data supporting its artificial intelligence (AI)-powered diabetes management platform.

New York-based Dario’s research examined users who were given access to a new product experience designed to drive better health habits and behaviors through its AI-driven personalization engine.

According to a news release, results —presented at the American Diabetes Association (ADA) 81st Scientific Sessions — for close to 10,000 members suggested that personalized interventions better help users understand the relationship between their behaviors and their health indicators, with user engagement increasing by 56% compared to the engagement baseline of all users before the new experience.

Results remained stable, with average ratios of high-blood glucose readings (180-400 mg/dL) reducing by 12% over six months, Dario said.

A second study of 11,101 high-risk, type 2 diabetic members after 12 months of engagement found that the average ratio of target in-range readings increased significantly from 28.4% to 54.8%, while the average number of days between blood glucose readings (recency) for Dario members was 3.3 days.

“Consistent self-management of health conditions is one of the most crucial healthy behaviors we can help our members develop, and also one of the most difficult,” DarioHealth scientific & clinical director Yifat Hershcovitz said in the release. “Customizing the experience of health management with real-time data and feedback to offer tangible, actionable insights drives better engagement which leads to positive behavior change and improved clinical outcomes.”

“This study offers yet more data supporting our personalized approach as a means to drive sustainable behavior change for improved clinical outcomes,” added DarioHealth CMO Dr. Omar Manejwala.

Filed Under: Clinical Trials, Diabetes, Featured, Patient Monitoring Tagged With: dariohealth

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS